CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An extensive version (31 slide illustrations) and executive summary (six slide illustrations) have both been lodged with the ASX.

CLINUVEL is focussing on the commercialisation of the medicinal product SCENESSE®(afamelanotide controlled-release) for the treatment of erythropoietic protoporphyria (EPP) in the European Union, United States and - since 26 October - Australia.

The Update reveals CLINUVEL's strategic intentions and ongoing work to translate the use of melanocortins and associated knowhow into non-prescription skin care products aiming to provide DNA-protective and reparative properties.

Attachments

  • Original document
  • Permalink

Disclaimer

Clinuvel Pharmaceuticals Limited published this content on 28 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 October 2020 01:39:08 UTC